Tranexamic Acid for Facelift Surgery

Phase < 1

Recruiting

Led By Jenna Van Beck, MD

Research Sponsored by University of Minnesota

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

age 18 and older

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 weeks post-op

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing the use of tranexamic acid (TXA) during facelift surgery to prevent prolonged bleeding. TXA will be applied to one side of the face in different forms,

Who is the study for?

This trial is for adults over 18 who choose to have a facelift and are considered fit for the surgery by their doctor. It includes those having additional procedures, but participants must speak English.

What is being tested?

The study tests Tranexamic acid (TXA) applied during facelifts to reduce bleeding. There are three ways TXA will be used: mixed with standard local anesthetic, as a higher concentration on soaked pledgets, or both methods combined.

What are the potential side effects?

While systemic use of TXA can increase blood clot risks in certain patients, this trial uses it topically or locally, which has not shown these adverse effects in previous studies on facial plastic surgery.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 weeks post-op

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 weeks post-op

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 weeks post-op for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Blood loss

Secondary study objectives

adverse effects of TXA rates

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

3Treatment groups

Experimental Treatment

Group I: Group 3Experimental Treatment1 Intervention

1% TXA with local plus 3% TXA-soaked pledgets with saline as the control Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control.

Group II: Group 2Experimental Treatment1 Intervention

3% TXA on TXA-soaked pledgets applied for 10 minutes with saline as the control Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control.

Group III: Group 1Experimental Treatment1 Intervention

1% TXA mixed with standard local consisting 1/4% lidocaine with 1:100,000 epinephrine with saline as the control. Each face is treated as a split face and one half gets randomized to a TXA containing treatment group, so that each participant serves as his/her own control.

0 / 1Eligibility criteria met